111592 ⎘
ssRNA viruses positive-sense; Details; Picornaviridae; Poliovirus Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
IRRADIATION-INACTIVATED POLIOVIRUS, COMPOSITIONS INCLUDING THE SAME, AND METHODS OF PREPARATION
#2ATTENUATED VIRUSES USEFUL FOR VACCINES
#3MICROMOLDED OR 3-D PRINTED PULSATILE RELEASE VACCINE FORMULATIONS
#4RECOMBINANT ENTEROVIRUSES AND USES THEREOF
#5VACCINE FORMULATIONS WITH INCREASED STABILITY
#6IMMUNOGENIC COMPOSITION COMPRISING CYAA-DERIVED POLYPEPTIDE PROMOTING A TH1/TH17-ORIENTED IMMUNE RESPONSE
#7MICRODEVICES WITH COMPLEX GEOMETRIES
#8Micromolded or 3-D printed pulsatile release vaccine formulations
#9Irradiation-inactivated poliovirus, compositions including the same, and methods of preparation
#10compositions and methods thereof
#11Process for enterovirus purification and inactivation and vaccine compositions obtained thereof
#12Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
#13IMMUNOGENIC COMPOSITION
#14Poliovaccine
#15Micromolded or 3-D printed pulsatile release vaccine formulations
#16IMMUNOGENIC COMPOSITION COMPRISING CYAA-DERIVED POLYPEPTIDE PROMOTING A TH1/TH17-ORIENTED IMMUNE RESPONSE
#17Immunogenic composition
#18VACCINE FORMULATIONS WITH INCREASED STABILITY
#19Codon optimization for increasing transgene expression in chloroplasts of higher seed plants
#20METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION
#21Multivalent vaccine composition
#22N-antigenic form poliovirus virus-like particles comprising thermostable mutations
#23Picornavirus-like particle production in plants
#24Recombinant HCMV and RHCMV vectors and uses thereof
#25Attenuated viruses useful for vaccines
#26Antigens and vaccines directed against human enteroviruses
#27COMBINATION VACCINES WITH LOWER DOSES OF ANTIGEN AND/OR ADJUVANT
#28Antigens and vaccines directed against human enteroviruses
#29Adjuvanted formulations of booster vaccines
#30Combination vaccines with lower doses of antigen and/or adjuvant
#31Immunogenic composition
#32Immunogenic composition
#33Methods and compositions for stabilizing dried biological materials
#34compositions and methods thereof
#35METHOD FOR AMELIORATING AND ABATING SYMPTOMS RESULTING FROM RHEUMATOID ARTHRITIS, FIBROMYALGIA, AND CHRONIC PAIN OF UNKNOWN ORIGIN
#36Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
#37Cold-adapted-viral-attenuation (CAVA) and novel attenuated poliovirus strains
#38Methods of making modified viral genomes
#39Immunogenic composition
#40Peptide/β-1,3-glucan complex and production method thereof and pharmaceutical composition containing peptide/β-1,3-glucan complex
#41Adjuvanted formulations of booster vaccines
#42Nasal mucosal vaccine composition
#43Mucosal vaccine composition
#44Mucosal vaccine composition
#45Methods of immunization with varicella zoster virus antigen
#46Methods for the prevention of aggregation of viral components
#47Recombinant HCMV and RHCMV vectors and uses thereof
#48Tumor vaccines and methods of use thereof
#49Immunogenic compositions comprising silicified virus and methods of use
#50VACCINE
#51Picornavirus-like particle production in plants
#52Immunogenic composition
#53Immunogenic compositions
#54Micromolded or 3-D printed pulsatile release vaccine formulations
#55Antigens and vaccines directed against human enteroviruses
#56ADJUVANTED FORMULATIONS OF PEDIATRIC ANTIGENS
#57compositions and methods thereof
#58Adjuvant formulations and methods
#59Immunogenic composition
#60Polyanionic polymer adjuvants for Haemophilus influenzae B saccharide vaccines
#61Methods and compositions for stabilizing dried biological materials
#62Method for formulating a vaccine containing at least two antigens capable of adsorbing onto aluminium oxyhydroxide
#63Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
#64Production of poliovirus at high titers for vaccine production
#65Immunization compositions and methods
#66Vaccination method employing genetically stable attenuated polioviruses comprising multiple mutations in domain V of the 5′ noncoding region
#67Inactivated poliovaccine
#68Combination heptavalent vaccine
#69Recombinant HCMV and RHCMV vectors and uses thereof
#70PRODUCTION OF POLIOVIRUS AT HIGH TITERS FOR VACCINE PRODUCTION
#71Multiple vaccination including serogroup C meningococcus
#72Multiple vaccination including serogroup C meningococcus
#73Process for manufacturing vaccines
#74Vaccine composition
#75POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZAE B SACCHARIDE VACCINES
#76MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH NON-HIB VACCINES
#77Multiple vaccination including serogroup C Meningococcus
#78Vaccine Composition
#79Combination vaccine with acellular pertussis
#80COMBINATION VACCINE WITH WHOLE CELL PERTUSSIS
#81Immunization compositions and methods
#82Drying process
#83Production of poliovirus at high titers for vaccine production
#84PROCESS FOR TREATMENT OF RHEUMATOID ARTHRITIS, TREMORS/PARKINSON'S DISEASE, MULTIPLE SCLEROSIS AND NON-VIRAL BASED CANCERS
#85PROCESS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, RHEUMATOID ARTHRITIS, TREMORS/PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, NON-VIRAL BASED CANCERS, ALZHEIMERS'S DISEASE, MUSCULAR DYSTROPHY, ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, COMPLEX REGIONAL PAIN SYNDROME, DIABETES, NEUROPATHIC PAIN, SPIDER ARTHRITIS, WEST NILE VIRUS, FIBROMYALGIA, SHINGLES, GOUT, MIGRAINE HEADACHES, SENILE DEMENTIA, POST POLIO SYNDROME, CENTRAL VIRUS DEAFNESS, ASTHMA, CHRONIC PAIN OF UNKNOWN ORIGIN AND HEPATITIS C
#86Polyanionic polymer adjuvants for B saccharide vaccines
#87COMBINATION VACCINES WITH 1-HYDROXY-2-PHENOXYETHANE PRESERVATIVE
#88Process for manufacturing vaccines
#89Attenuated viruses useful for vaccines
#90Genetically stable attenuated polioviruses comprising multiple mutations in domain V of the 5′ noncoding region
#91MANUFACTURE OF BOOSTER VACCINES HAVING REDUCED ANTIGEN DOSES
#92ATTENUATED VIRUSES, VACCINES AND METHODS OF USE THEREOF
#93PROCESS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, RHEUMATOID ARTHRITIS, TREMORS/PARKINSON'S DISEASE, MULTIPLE SCLEROSIS AND NON-VIRAL BASED CANCERS
#94VACCINE
#95Inactivated polio vaccines
#96Vaccine
#97Multiple vaccination including serogroup C meningococcus
#98IPV-DPT vaccine
#99Immunogenic composition
#100VERO CELL LINE WHICH IS ADAPTED TO GROW IN SUSPENSION
#101Immunogenic composition
#102Purification of HBV antigens for use in vaccines
#103Immunogenic composition
#104Conjugate Vaccines
#105Chimeric lyssavirus nucleic acids and polypeptides
#106Immunogenic composition
#107Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus
#108Immunogenic composition
#109VACCINE COMPOSITION
#110Vaccine Comprising a Polysaccharide Antigen-Carrier Protein Conjugate and Free Carrier Protein
#111Vero cell line adapted to grow in suspension
#112Prevention of type 1 diabetes and other non-polio enterovirus diseases
#113Method for processing and preserving collagen-based tissues for transplantation
#114Purification of HBV antigens for use in vaccines
#115Drying process
#116Immunogenic composition
#117Polyanionic polymer adjuvants for haemophilus influenzae B saccharide vaccines
#118Advanced oral poliovirus vaccine (Adv-OPV) deprived of the possibility of vaccine associated paralytic poliomyelities (VAPP)
#119Targeted adenovirus vectors for delivery of heterologous genes
#120Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
#121Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
#122Bacterial vectors and methods of use thereof
#123Chimeric lyssavirus nucleic acids and polypeptides